GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » D&D Pharmatech Inc (XKRX:347850) » Definitions » Ending Cash Position

D&D Pharmatech (XKRX:347850) Ending Cash Position : ₩37,763 Mil (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is D&D Pharmatech Ending Cash Position?

D&D Pharmatech's Ending Cash Position for the quarter that ended in Sep. 2024 was ₩37,763 Mil.

D&D Pharmatech's quarterly Ending Cash Position declined from Dec. 2023 (₩15,642 Mil) to Jun. 2024 (₩0 Mil) but then increased from Jun. 2024 (₩0 Mil) to Sep. 2024 (₩37,763 Mil).

D&D Pharmatech's annual Ending Cash Position declined from Dec. 2021 (₩75,958 Mil) to Dec. 2022 (₩25,504 Mil) and declined from Dec. 2022 (₩25,504 Mil) to Dec. 2023 (₩15,642 Mil).

D&D Pharmatech Ending Cash Position Historical Data

The historical data trend for D&D Pharmatech's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

D&D Pharmatech Ending Cash Position Chart

D&D Pharmatech Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position
Get a 7-Day Free Trial 113,057.18 60,611.52 75,957.51 25,503.74 15,642.05

D&D Pharmatech Quarterly Data
Dec22 Jun23 Sep23 Dec23 Jun24 Sep24
Ending Cash Position Get a 7-Day Free Trial - 18,611.16 15,642.05 - 37,763.24

D&D Pharmatech Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

D&D Pharmatech's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=25503.738+-9861.685
=15,642

D&D Pharmatech's Ending Cash Position for the quarter that ended in Sep. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=43324.619+-5561.383
=37,763

D&D Pharmatech Ending Cash Position Related Terms

Thank you for viewing the detailed overview of D&D Pharmatech's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

D&D Pharmatech Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » D&D Pharmatech Inc (XKRX:347850) » Definitions » Ending Cash Position
Comparable Companies
Traded in Other Exchanges
N/A
Address
4th floor, 24, Pangyo-ro 255beon-gil, Bundang-gu, Gyeonggi-do, Sampyeong-dong, I&C Building, Seongnam-si, KOR
Website
http://www.ddpharmatech.com
D&D Pharmatech Inc is a company that comprises of experts in the field of bio-new drug research and development and technology commercialization, including basic scientists in the pharmaceutical biofield, manufacturing quality control (CMC) experts, and clinical development and technology transfer experts. Other business areas include the development of positron emission tomography (PET) imaging biomarkers conducted by Precision Molecular Inc. a 100% subsidiary, and single-cell sequencing related to degenerative brain diseases conducted by Valted Seq, Inc. The company utilizes drug delivery technologies such as PEGylation technology, which helps extend the administration interval using PEG and various chemicals, and platform technology that converts injectable drugs into oral preparations.

D&D Pharmatech Headlines

No Headlines